CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies

In this engaging online program watch experts discuss emerging strategies and current best practices in CAR T-cell therapy for patients with lymphomas leukemias and myelomas. Download slides with all the key data view the on-demand Webcast and join the discussion with expert-authored commentaries and podcasts.

Share

Program Content

Activities

<i>EP</i>: CAR T-Cell Therapy
ExpressPoints: CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 18, 2021

Expires: February 17, 2022

CAR T-Cell Therapy
CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 11, 2021

Expires: February 10, 2022

Activities

CAR T/NHL Approvals
Expanding Approved CAR T-Cell Therapy Treatment Options for Patients With Lymphoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2021

Expires: March 11, 2022

Activities

Q&A: Myeloma and Toxicities
Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2021

Expires: March 11, 2022

<i>Pearls</i>: Myeloma and Toxicities
Podcast Pearls: Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities
Podcast Episodes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2021

Expires: March 11, 2022

Q&A: Lymphomas
Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 18, 2021

Expires: March 17, 2022

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Kite Pharma